Harvard Apparatus Regenerative Technology (HRGN) AI Stock Analysis

• Market Cap: $32.96M
• Dividend Yield: N/A
• Average Volume (3M): 1.91K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.18
• Revenue Growth: 214.35%
• EPS Growth: 24.82%
• Country: US
• Employees: 18
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.08
• Shares Outstanding: 17,168,980
• 10 Day Avg. Volume: 1,792
• 30 Day Avg. Volume: 1,912
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.81
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 37 Underperform
• Price Target: ―

HRGN faces significant financial challenges, with persistent net losses and cash flow issues. The technical indicators suggest a bearish trend, and the valuation is unattractive with a negative P/E ratio. The lack of positive earnings call updates contributes to a low overall stock score.

Harvard Apparatus Regenerative Technology Business Overview & Revenue Model

Company Description

Biostage, Inc. is a biotechnology company, which engages in the development of organ implants to treat congenital defects, cancers, and life-threatening conditions of the esophagus, bronchus and trachea. It operates through Cellframe technology, engineered to stimulate the body's signaling pathways and natural healing process to regenerate and restore organ function. The company was founded on May 3, 2012 and is headquartered in Holliston, MA.

How the Company Makes Money

HRGN makes money through the commercialization of its bioengineered organ products and regenerative medicine therapies. Revenue is generated from the sale of these products to healthcare providers, research institutions, and potentially through partnerships with other biotech firms. The company may also earn income through licensing agreements, where it licenses its technology to other companies for development or commercial use. Additionally, HRGN might receive funding or grants from government or private entities interested in advancing regenerative medicine technologies. Key revenue streams include product sales, licensing fees, and potentially milestone payments from collaborations or partnerships.

Harvard Apparatus Regenerative Technology Financial Statement Overview

Summary

Harvard Apparatus Regenerative Technology faces ongoing financial challenges. Despite some revenue growth, significant net losses and negative cash flows persist. Leverage is low, but the company struggles with negative equity. Profitability and cash flow issues need addressing for improved stability.

Income Statement

The company has demonstrated revenue growth from 2022 to 2023, with a 18.39% increase. However, it is still operating at a net loss, with a negative net profit margin of -8683.50%. Gross profit margin improved to 76.70% in 2023, but the EBIT and EBITDA margins remain significantly negative. Overall, the profitability metrics indicate significant challenges in achieving positive earnings.

Balance Sheet

The company's debt-to-equity ratio is relatively low, indicating manageable leverage. However, the equity ratio is 61.30%, showing reliance on equity financing. The return on equity is negative due to net losses, and the company has struggled with negative stockholders' equity in past years. These factors highlight ongoing financial instability.

Cash Flow

Free cash flow has deteriorated further from 2022 to 2023, declining by 35.97%. The operating cash flow to net income ratio is positive, suggesting better cash generation relative to net income losses, but the free cash flow to net income ratio remains negative, indicating cash flow challenges.

Breakdown	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	―	―	―	―	―
Gross Profit	79.00K	87.00K	―	―	―
EBITDA	-8.80M	-6.20M	-8.36M	-4.69M	-8.12M
Net Income	-8.95M	-6.07M	-7.98M	-4.87M	-8.33M
Balance Sheet
Total Assets	2.61M	2.40M	1.87M	2.08M	1.99M
Cash, Cash Equivalents and Short-Term Investments	―	―	―	―	―
Total Debt	48.00K	147.00K	169.00K	586.00K	191.00K
Total Liabilities	968.00K	1.41M	4.89M	951.00K	903.00K
Stockholders Equity	―	―	―	―	―
Cash Flow
Free Cash Flow	-6.95M	-5.11M	-2.63M	-4.05M	-6.19M
Operating Cash Flow	-6.94M	-5.11M	-2.63M	-4.04M	-6.06M
Investing Cash Flow	―	―	―	―	―
Financing Cash Flow	―	―	―	―	―

Harvard Apparatus Regenerative Technology Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.84
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HRGN, the sentiment is Positive. The current price of 1.84 is above the 20-day moving average (MA) of 1.77, above the 50-day MA of 1.61, and below the 200-day MA of 2.06, indicating a neutral trend. The MACD of 0.08 indicates Negative momentum. The RSI at 58.25 is Neutral, neither overbought nor oversold. The STOCH value of 86.27 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HRGN.

Harvard Apparatus Regenerative Technology Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FBIO	54 Neutral	109.80M	-3.28	-202.30%	―	-28.23%	93.42%
RGLS	52 Neutral	520.01M	-8.96	-60.67%	―	―	44.85%
PSTV	48 Neutral	40.12M	-0.25	145.02%	―	-3.49%	27.88%
ADAP	41 Neutral	35.91M	-0.19	239.23%	―	-53.61%	-93.14%
HRGN	37 Underperform	$32.96M	―	-2839.07%	―	214.35%	24.82%
CLRB	34 Underperform	18.45M	-0.28	―	―	―	73.37%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%